Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.

Hemodynamic Changes and Prognostic Analysis of Patients With Locally Advanced Non-small Cell Lung Cancer During Combined Chemoradiotherapy and Immunotherapy: An Observational Study Based on Dynamic Cardiac Output.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06277388

Enrollment

231

Registered

2024-02-26

Start date

2021-06-05

Completion date

2026-06-30

Last updated

2026-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer, Cardiac Toxicity

Keywords

Non-small Cell Lung Cancer, impedance cardiography, concurrent chemoradiotherapy

Brief summary

This study aimed to investigate the role of impedance cardiography (ICG) in evaluating hemodynamic changes during the 6-minute walk test (6MWT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who underwent combined concurrent chemoradiotherapy (CCRT) and immunotherapy. Additionally, It sought to analyze the predictive significance of cardiac parameters to both treatment toxicity and survival prognosis.

Interventions

DEVICEImpedance cardiography

The study conducted a 6-minute walk test (6MWT) in a hospital hallway following ATS guidelines. Patients rested for 10 minutes before the test. Impedance measurements were taken before (2 minutes), during (6 minutes), and after (3 minutes) the walk, recording cardio-dynamic parameters with impedance cardiography (ICG).

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. had untreated histologically or cytologically confirmed NSCLC 2. be between the age of 18 and 75 3. had unresectable stage IIIA-IIIC disease, as defined by the AJCC 8th edition staging system 4. had an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0\~1 5. had adequate bone marrow function (neutrophil count ≥1.5x109/L, hemoglobin concentration ≥90 g/L, platelet ≥100x109/L), kidney function (serum creatinine clearance ≥50 ml/min) and liver function (serum bilirubin ≤1.5 times upper limit of normal (ULN), aspartate transaminase (AST) and alanine transferase (ALT) ≤2.5 ULN) 6. had a forced expiratory volume in 1 second (FEV1) of ≥0.8L.

Exclusion criteria

1. mixed small cell and NSCLC histology 2. life expectancy lower than 12 weeks 3. history of another primary malignancy 4. poorly controlled intercurrent illness 5. female in pregnancy or breast-feeding and any situation not suitable for this study judged by researchers 6. patients with contraindications to 6MWT, including unstable angina pectoris or myocardial infarction within the past month, systolic blood pressure (SBP) over 180mmHg, diastolic blood pressure (DBP) over 100mmHg, muscle strength below grade 3, and severe spasm.

Design outcomes

Primary

Measure	Time frame	Description
Stroke volume（SV）	From enrollment to 2 year after radiotherapy	The volume of blood ejected from the left ventricle of the heart in one contraction or heartbeat.

Countries

China

Contacts

PRINCIPAL_INVESTIGATORHui Liu, MD

Sun Yat-sen University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026